DWA
ENTA icon

Dorsey Wright & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Dorsey Wright & Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-240
Closed -$21K – 295
2018
Q3 		$21K Buy
+240
New +$24K ﹤0.01% 154

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dorsey Wright & Associates's ENTA Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 240 shares — an estimated $21K sold.

Dorsey Wright & Associates first reported a position in ENTA in Q3 2018 and held it in 1 quarter. The position peaked at $21K in Q3 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 240 Enanta Pharmaceuticals shares in Q4 2018, an estimated $21K.
  • Dorsey Wright & Associates first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Enanta Pharmaceuticals position peaked at $21K in Q3 2018.
  • 183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.